An ancillary stack for managing estrogen on an aromatising cycle — an AI primary with a SERM on standby for symptoms.
On an aromatising anabolic cycle, rising estrogen can cause side effects. The standard ancillary is an aromatase inhibitor (anastrozole or exemestane) dosed conservatively to keep estrogen in range rather than crush it — over-suppression brings joint, lipid, libido, and mood problems.
A SERM (tamoxifen) is kept on standby for gyno symptoms specifically — on the shelf, not in the cycle: the compound pages flag anastrozole with tamoxifen as a pair to avoid (tamoxifen lowers anastrozole's levels), and two aromatase inhibitors together are never the answer. That is why only anastrozole is in the buildable stack, with exemestane as the swap if it is better tolerated. This is pure harm-reduction context for people already on cycle; the recurring theme is that estrogen management is bloodwork-guided and easy to overdo.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Anastrozole AI; dose conservatively — don't crush estrogen. | Primary | 0.25-0.5mg EOD or E3D (estrogen management) | Every other day to every 3 days (cycle support); daily (breast cancer) |
Last updated . How this page was sourced is described in the methodology.